Dronedarone-digoxin interaction in PALLAS: A foxglove connection?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a common arrhythmia requiring effective management.
• Dronedarone is an antiarrhythmic drug used in AF management.
• Digoxin is frequently used in patients with heart failure and AF.

Purpose of the Study:

• To investigate the safety and efficacy of dronedarone in patients with permanent atrial fibrillation.
• To explore potential drug interactions between dronedarone and digoxin.

Main Methods:

• The study involved patients with permanent atrial fibrillation receiving standard therapy plus dronedarone or placebo.
• A subanalysis focused on patients also taking digoxin to assess drug interactions.

Main Results:

• Dronedarone use was linked to increased risks of stroke, cardiovascular death, and hospitalizations.
• Elevated serum digoxin levels were observed in the dronedarone group, indicating P-glycoprotein inhibition.
• The digoxin-dronedarone interaction was implicated in the higher rate of arrhythmic death.

Conclusions:

• Dronedarone use in AF patients is associated with significant adverse events, potentially exacerbated by digoxin co-administration.
• The interaction between dronedarone and digoxin poses a considerable risk, particularly concerning arrhythmic death.
• Clinicians should exercise caution and consider safer alternatives to digoxin in AF patients, especially when dronedarone is prescribed.